Webster agrees Lifecore buyout with cash and contingent payments
Lifecore Biomedical ($LFCR) has agreed to be acquired by a Webster Equity Partners affiliate. Common shareholders would receive $6.28 in cash per share at closing, a 49.5% premium to the preceding trading day’s close, plus a non-tradable contingent value right. The company described a potential transaction value of up to $663.7 million, assuming all relevant financial milestones are achieved. The contingent component could distribute up to $160 million in aggregate, but depends on future revenue
0